Regeneron Advances Early-Stage Eye Drug Pozelimab in Geographic Atrophy Trial

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study.

Study Overview

Regeneron Pharmaceuticals is running a Phase 1 study titled “A Phase 1 Dose-Escalation and Repeated-Dose Study of the Safety and Tolerability of Intravitreal Pozelimab in Participants With Geographic Atrophy.” The goal is to test how safe and tolerable pozelimab eye injections are for adults with geographic atrophy, a progressive eye disease that harms central vision. This early-stage study matters because it explores a new way to slow vision loss in an area where long-term treatment options remain limited.

Intervention/Treatment

The study tests an experimental drug called pozelimab. It is given as an injection into the eye (intravitreal). The drug is designed to act on the immune system pathways believed to drive retinal damage, with the aim of slowing or stabilizing the loss of retinal cells and vision in people with geographic atrophy.

Study Design

This is an interventional trial with participants randomly assigned to different dose levels and schedules of pozelimab. The study runs in two parts. Part A is open label, meaning both doctors and patients know the dose being given. Part B is masked, so patients, care teams, investigators, and outcome assessors do not know which specific regimen is used, reducing bias in safety and early efficacy readouts. The main goal is treatment-focused: to understand how patients respond to repeated eye injections of pozelimab.

Study Timeline

The trial was first submitted in November 2025, marking the formal start of regulatory and operational planning. The most recent update to the record was posted on January 13, 2026, signaling that the protocol and status are current and that the study remains active and recruiting. Primary completion and final completion dates are not yet reported, which is typical for an early-stage program still enrolling and adjusting dose schedules.

Market Implications

For investors, this update reinforces Regeneron’s push deeper into retinal disease beyond its core Eylea franchise. A positive safety and tolerability profile for intravitreal pozelimab would support progression to larger trials, helping Regeneron build a long-term pipeline in geographic atrophy, a market now drawing strong interest after recent approvals from other players. While Phase 1 data seldom moves the stock on their own, continued advancement could be viewed as an incremental positive for sentiment, especially as Regeneron responds to growing competition in age-related macular degeneration and atrophy from firms like Apellis and Iveric (Astellas). The main near-term takeaway is that Regeneron is actively investing in future ophthalmology revenue streams, which supports the company’s longer-term growth story.

The study remains ongoing and updated, with further details available on the ClinicalTrials portal.

To learn more about REGN’s potential, visit the Regeneron Pharmaceuticals drug pipeline page.